How to buy DexCom (DXCM) stock from India

Yes, an Indian resident can buy DexCom — legally, in US dollars, under the RBI's Liberalised Remittance Scheme (LRS). The buying is the easy 10%. The 90% that decides your outcome is tax, estate-tax exposure, and position sizing. DXCM has one helpful quirk: it pays no dividend, so US withholding and Form 67 paperwork are essentially a non-issue. This is the short version.

The 30-second version

• Legal and simple. Buy DXCM via any India-facing platform (Vested, INDmoney) or a global broker (Interactive Brokers, Rovia). Whole shares or a fractional rupee amount.
• Pure capital-gains play. DXCM has never paid a dividend and reinvests cash flow into G7, Stelo, and international expansion, so US dividend withholding and Form 67 are essentially irrelevant for this name.
• India tax: hold more than 24 months and pay 12.5% LTCG (no indexation); sell sooner and pay your slab rate. This is Section 112, not the friendlier 112A that Indian shares get.
• The trap most miss: directly-held DXCM is a US-situs asset — above $60,000, your estate faces up to 40% US estate tax, with no India-US treaty relief.
• If your thesis is "medical devices," IHI or XHE hold DXCM with broader device exposure; QQQ, VOO, and VTI also hold it at smaller weights.

Quick facts

Can an Indian resident buy it?	Yes — fully legal under the LRS
Ticker / exchange	DXCM / Nasdaq
How	India-facing platform (Vested, INDmoney) or global broker (IBKR, Rovia)
Minimum	A fraction of one share (fractional lets you invest an exact rupee amount)
Dividend	None — DXCM reinvests cash flow into the sensor platform and Stelo
India tax on gains	12.5% LTCG after 24 months; else your slab (Section 112)
Estate-tax risk	US-situs above $60k means up to 40%, no treaty relief
Annual compliance	Schedule FA disclosure, every year you hold

How to buy it — 3 steps

1. Open an account and finish KYC. Pick an India-facing platform (Vested, INDmoney) for a simple India-funded experience, or a global broker (Interactive Brokers, Rovia) for wider access. File your W-8BEN during onboarding — still good practice even with no current dividend, because it covers any future distribution. New to this? Start with how to invest in US stocks from India.
2. Fund it via the LRS. Remit from your Indian bank under the LRS (cap: $250,000 per financial year). 20% TCS applies above ten lakh rupees in a year — a creditable prepayment, not a cost. See LRS explained and the LRS and TCS calculator.
3. Place the order. DexCom completed a 4-for-1 stock split in June 2024, dropping a single share from the mid-three-hundreds to a far more accessible level — so a whole share is now affordable, or buy a fractional rupee amount.

The tax that actually matters

DexCom pays no dividend, so the 25% US withholding and annual Form 67 foreign-tax-credit dance — a recurring headache with names like Microsoft or Apple — does not apply here. Your entire tax exposure is on capital gains when you sell, under Section 112 (foreign shares don't get the Section 112A treatment Indian-listed equity enjoys):

Holding period	Treatment	Rate
24 months or less	Short-term	Your slab rate (up to roughly 30% plus surcharge)
More than 24 months	Long-term	12.5%, no indexation

Worked example. Buy 10 shares at $80 when USD/INR is 86 → cost 68,800 rupees. Sell 26 months later at $105 when USD/INR is 88 → proceeds 92,400 rupees. Taxable gain 23,600 rupees; LTCG at 12.5% = 2,950 rupees. The gain is computed in rupees, so a weaker rupee at sale amplifies your reported gain. Model your own with the US capital-gains calculator; full rules in how US stocks are taxed in India. For context on Form 67 (relevant if you also hold dividend-paying US names), see dividend withholding and Form 67.

The $60,000 estate-tax trap

Directly-held DXCM is a US-situs asset. If the holder dies with more than $60,000 of US-situs assets, the estate faces US estate tax up to 40% — and the India-US treaty does not cover estate tax, so there's no credit or relief. The fix (holding through pooled or fund structures rather than direct shares) has to be a deliberate choice made before the position gets large. Full detail: the $60,000 estate-tax trap.

Buy the stock, or get DexCom through an ETF?

If you want…	Best route
A concentrated bet that DXCM out-executes Abbott in CGM	DXCM directly
"Medical devices will keep compounding" exposure	IHI or XHE — DXCM sits alongside Boston Scientific, Stryker, Medtronic
Broad US-large-cap exposure that incidentally holds DXCM	VOO, VTI, or QQQ — smaller weights, hundreds of other names
The least single-stock risk	A broad ETF

DexCom sits in IHI (iShares medical-devices) and XHE (SPDR healthcare-equipment) at meaningful weights, and in broad funds like VOO, VTI, and QQQ at smaller weights. A device ETF gives you DXCM plus Boston Scientific, Stryker, Medtronic, Intuitive Surgical — one Schedule FA entry and cleaner estate-tax treatment via pooled vehicles. Compare the routes in direct stocks vs US ETFs and best US ETFs for Indian investors; the broader case is in US ETFs for Indians.

The business in one screen

What it is: DexCom is one of two dominant players in continuous glucose monitoring (CGM) — a high-margin recurring-sensor business. The flagship G7 is the latest 10-day-wear sensor, smaller and more accurate, integrated with insulin pumps and smartphones. Stelo, launched late 2024, is the first OTC glucose biosensor in the US, aimed at non-insulin Type 2 patients and metabolic-health consumers — opening a much broader TAM beyond Type 1 diabetes. The competitive set is essentially two players: DexCom and Abbott's FreeStyle Libre.

Bull case	Bear case
CGM category growth is structural (T2 adoption, pre-diabetes, GLP-1 monitoring)	Abbott Libre is gaining US Type 2 / non-insulin share
G7 platform — smaller form factor, 10-day wear, tighter accuracy	Pharmacy-channel pricing pressure as volumes shift away from DME
Stelo OTC unlocks consumer-health TAM beyond diabetes	Rising DTC marketing spend pressures operating margin
International expansion (Europe, Asia, eventually India)	OTC and GLP-1-adjacent monitoring still nascent revenue
High-margin recurring-sensor model with strong gross margins	Valuation has rerated lower but EV/EBITDA still premium to device peers

Exact valuation is in the live widget above — a duopoly category leader, priced for continued execution against a strengthening Abbott.

Our take

Verdict: HOLD — CGM is one of the great medical-device categories, but DexCom shares its lane with a credible, larger competitor in Abbott, and near-term US growth has decelerated. The structural story is intact; the entry price is the question.

• Two-player market, and the other player is winning share. Abbott's FreeStyle Libre has been gaining US Type 2 / non-insulin-dependent share through pharmacy distribution and price. G7 plus Stelo is the right response, but it's a defence of share rather than uncontested expansion.
• The long-term TAM is genuinely large. Pre-diabetes, metabolic-health consumers, and GLP-1 patient monitoring are all real, and Stelo is the first OTC consumer-grade glucose biosensor. Monetisation here is still early; the next two to three quarters of US volume and Stelo uptake will tell you which way it breaks.
• Better entry on a Q4 disappointment. The stock has rerated lower from its 2023 highs, but EV/EBITDA stays premium to broader device peers. A weak quarter on US growth or Stelo traction would create a more interesting entry. Today, hold and watch.

Compliance note. Vested.blog is not a SEBI-registered Research Analyst. The above is an editorial opinion for educational illustration only — not investment advice and not a regulated stock recommendation. Vested.blog is published by Rovia; the publisher and its affiliates may hold positions in stocks discussed. Make your own decisions or consult a SEBI-registered advisor.

Risks to size for

• Abbott share gains: the single biggest risk is not a category collapse but ongoing share loss to FreeStyle Libre in the US non-insulin-dependent segment. Watch quarterly US new-patient adds.
• Pricing and channel mix: as CGM volume moves to pharmacy and OTC, gross margin and ASPs face pressure that pure-DME-era multiples didn't price in.
• Currency: your return is in USD but you spend rupees — see the rupee-dollar effect.

Two things people forget

• Schedule FA: disclose DXCM in Schedule FA of your ITR every year you hold it — even if bought and sold within the year, even at a loss. Non-disclosure carries Black Money Act penalties. Because DXCM pays no dividend, you skip Form 67 for this position — but Schedule FA is non-negotiable. Use the Schedule FA helper.
• Position size: a single name in a two-player category carries both single-stock and competitive-dynamic risk. Size DXCM as a thematic satellite, not a substitute for a broad ETF.

The Indian-investor angle

Diabetes is a real Indian category — India has one of the largest diabetic populations in the world, and brand recognition for DexCom and FreeStyle Libre among urban patients and endocrinologists is genuine. DXCM is not in Indian retail pharmacies yet, and pricing is the open commercial question — a long-dated international TAM, not a near-term revenue line.

Bottom line

Buying DXCM from India is easy and legal. What needs thought isn't the buying — it's that DXCM is a Section-112 capital-gains play (12.5% after 24 months), a US-situs asset with a $60k estate-tax trap, and a single name in a two-player category facing real competitive pressure from Abbott. The upside: no dividend means no 25% withholding and no Form 67. If your real thesis is "medical devices keep compounding," IHI or XHE give category exposure without the head-to-head Abbott risk. For accounts and options, start at the US investing hub.

---

This article is general information, not personalised investment, tax, or legal advice. Rules, rates, and thresholds described here are as of 2026 and can change; verify the current position and consult a qualified advisor before acting.